Cabaletta Bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Cabaletta BioDer Gewinn des Unternehmens wird voraussichtlich um 10% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 88.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 0.04% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -135.9% betragen.

Wichtige Informationen

-10.0%

Wachstumsrate der Gewinne

-0.04%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	88.3%
Zukünftige Eigenkapitalrendite	-135.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Jun 04

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Feb 11

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Jul 07

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Mar 24

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 09

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Aug 05

Cabaletta Bio EPS beats by $0.08

May 03

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Apr 12

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Feb 19

Chardan Capital initiates Cabaletta Bio with Buy rating

Jan 08

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 28

Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder

Dec 09

Cabaletta Bio +5% on Q3 results, pipeline update

Nov 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CABA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2	-170	-124	-115	7
12/31/2025	N/A	-143	-119	-103	7
12/31/2024	N/A	-115	-98	-81	7
9/30/2024	N/A	-104	-84	-82	N/A
6/30/2024	N/A	-90	-76	-74	N/A
3/31/2024	N/A	-77	-66	-65	N/A
12/31/2023	N/A	-68	-54	-54	N/A
9/30/2023	N/A	-62	-50	-49	N/A
6/30/2023	N/A	-57	-48	-47	N/A
3/31/2023	N/A	-56	-49	-46	N/A
12/31/2022	N/A	-53	-49	-46	N/A
9/30/2022	N/A	-51	-47	-45	N/A
6/30/2022	N/A	-51	-45	-43	N/A
3/31/2022	N/A	-50	-39	-38	N/A
12/31/2021	N/A	-46	-35	-34	N/A
9/30/2021	N/A	-42	-34	-33	N/A
6/30/2021	N/A	-39	-30	-29	N/A
3/31/2021	N/A	-36	-31	-31	N/A
12/31/2020	N/A	-33	-27	-27	N/A
9/30/2020	N/A	-29	-26	-25	N/A
6/30/2020	N/A	-26	-23	-23	N/A
3/31/2020	N/A	-21	-19	-19	N/A
12/31/2019	N/A	-22	-17	-16	N/A
9/30/2019	N/A	-19	-10	-10	N/A
6/30/2019	N/A	-23	-9	-9	N/A
3/31/2019	N/A	-21	-6	-6	N/A
12/31/2018	N/A	-12	-5	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CABA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CABA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CABA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CABA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CABA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CABA wird voraussichtlich in 3 Jahren unrentabel sein.

Cabaletta Bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 8.5% to US$30.38

Price target increased by 26% to US$17.00

Price target increased by 10% to US$14.17

Price target increased to US$9.00

Price target decreased to US$9.33

Price target decreased to US$10.60

Recent updates

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

New major risk - Revenue and earnings growth

New major risk - Share price stability

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

New major risk - Revenue and earnings growth

Cabaletta Bio, Inc., Annual General Meeting, Jun 03, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Cabaletta Bio, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

President of Science & Technology exercised options and sold US$204k worth of stock

Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

President of Science & Technology exercised options and sold US$230k worth of stock

President of Science & Technology notifies of intention to sell stock

Price target increased by 8.5% to US$30.38

Cabaletta Bio, Inc. Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

President of Science & Technology exercised options and sold US$136k worth of stock

Cabaletta Bio, Inc. Receives U.S. Food and Drug Administration Clearance of Investigational New Drug Application for Treatment of Systemic Sclerosis with CABA-201

President of Science & Technology notifies of intention to sell stock

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

President of Science & Technology exercised options and sold US$136k worth of stock

Cabaletta Bio, Inc. Appoints Shawn Tomasello to Its Board of Directors

President of Science & Technology notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target increased by 26% to US$17.00

President of Science & Technology exercised options and sold US$132k worth of stock

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

President of Science & Technology exercised options and sold US$238k worth of stock

Price target increased by 10% to US$14.17

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$9.00

High number of new and inexperienced directors

Co-Founder recently bought US$141k worth of stock

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio, Inc. Announces CABA-201, a Newly Designed, Fully Human CD19 Chimeric Antigen Receptor (CAR) Containing a 4-1Bb Co-Stimulatory Domain

Price target decreased to US$9.33

Price target decreased to US$10.60

Cabaletta Bio to Present Data At the 31St Eadv Congress and Provides Update on Descaartes™ Trial

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio Presents Updated Interim Descaartes™ Trial Phase 1 Data At the Asgct 25Th Annual Meeting

Price target decreased to US$14.17

Cabaletta Bio, Inc. to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May

Price target decreased to US$15.67

High number of new and inexperienced directors

Cabaletta Bio, Inc., Annual General Meeting, Jun 01, 2022

Jakubowitz Law Reminds Cabaletta Bio, Inc. Shareholders of A Lead Plaintiff Deadline of April 29, 2022

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART

Pomerantz LLP Law Firm Announces the Filing of Class Action Against Cabaletta Bio, Inc., and Certain Officers

Co-Founder exercised options to buy US$144k worth of stock.

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

Price target decreased to US$18.83

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes Trial in Patients with mPV

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Cabaletta Bio, Inc.(NasdaqGS:CABA) dropped from Russell Microcap Value Index

Cabaletta Bio, Inc. Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial

Cabaletta Bio EPS beats by $0.08

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

New 90-day low: US$12.20

Chardan Capital initiates Cabaletta Bio with Buy rating